Loading clinical trials...

Addressing Barriers to Palliative Care Use in Bladder Cancer | Clinical Trials | Clareo Health

COMPLETED

Addressing Barriers to Palliative Care Use in Bladder Cancer

Addressing Barriers to Palliative Care Use in Bladder Cancer Through Better Understanding of Knowledge and Belief Development

NCT04598724•H. Lee Moffitt Cancer Center and Research Institute

View on ClinicalTrials.gov

Summary

Investigators plan to establish an in-depth understanding of knowledge and beliefs about palliative care in advanced Bladder Cancer patients and their caregivers, and to identify factors associated with positive and negative experiences with palliative care services among those who have received them.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Eligibility for both patient and caregiver participants will include:
•age ≥18 years
•able to speak and read English
•cognitively able to participate in study tasks
•willing to participate in surveys, semi-structured interviews, and/or focus groups
•able to participate in either a Zoom meeting or phone interview
•able to complete an emailed or paper survey
•Patient Participants: a diagnosis of muscle-invasive or locally advanced bladder cancer (stages II-IV).

Exclusion Criteria

•Patients and caregivers will be excluded if unable to provide verbal or written consent

Locations (1)

Moffitt Cancer Center

Tampa, Florida, United States

Key Dates

Start Date

December 22, 2020

Primary Completion Date

May 10, 2021

Completion Date

May 10, 2021

Last Updated

January 3, 2023

Enrollment

ACTUAL participants

Conditions

Muscle-Invasive Bladder CarcinomaBladder Cancer Stage IIBladder Cancer Stage IIIBladder Cancer Stage IV

Interventions

Surveys

OTHER

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069

Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia+60 more

View study

RECRUITINGNA

Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study

NCT07339761

Bladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 3, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Addressing Barriers to Palliative Care Use in Bladder Cancer

Inclusion Criteria

Exclusion Criteria

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers

Prophylactic Antibiotics in Cystectomy With Diversion

NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment